| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -5.32 | 7.25 | 40.3 | 10.41 |
Op profit growth | -17.74 | 9.64 | 28.96 | 9.82 |
EBIT growth | -23.14 | 13.92 | 23.21 | 6.28 |
Net profit growth | -50.36 | 88.44 | 16.82 | 5.27 |
Profitability ratios (%) | ||||
OPM | 18.7 | 21.52 | 21.05 | 22.91 |
EBIT margin | 15.26 | 18.8 | 17.7 | 20.15 |
Net profit margin | 11.29 | 21.53 | 12.25 | 14.71 |
RoCE | 12.79 | 18.29 | 20.44 | 21.98 |
RoNW | 2.84 | 6.88 | 4.96 | 5.75 |
RoA | 2.36 | 5.23 | 3.53 | 4.01 |
Per share ratios (₹) | ||||
EPS | 45.18 | 91.04 | 48.54 | 41.35 |
Dividend per share | 9 | 4 | 3 | 2.5 |
Cash EPS | 25.96 | 73.03 | 31.81 | 31.83 |
Book value per share | 419.42 | 374.28 | 287.15 | 199.35 |
Valuation ratios | ||||
P/E | 14.8 | 9.68 | 8.5 | 13.47 |
P/CEPS | 25.75 | 12.06 | 12.98 | 17.5 |
P/B | 1.59 | 2.35 | 1.43 | 2.79 |
EV/EBIDTA | 8.04 | 9.01 | 5.37 | 9.32 |
Payout (%) | ||||
Dividend payout | 9.95 | 0 | 0 | 6.04 |
Tax payout | -20.54 | -43.83 | -24.13 | -25.24 |
Liquidity ratios | ||||
Debtor days | 58.47 | 57.59 | 58.43 | 64.8 |
Inventory days | 129.16 | 123.32 | 107.12 | 112.94 |
Creditor days | -58.64 | -55.93 | -53.39 | -70.89 |
Leverage ratios | ||||
Interest coverage | -73.61 | -62.54 | -13.4 | -42.7 |
Net debt / equity | -0.05 | 0 | 0.17 | 0.3 |
Net debt / op. profit | -0.3 | -0.02 | 0.61 | 0.92 |
Cost breakup (₹) | ||||
Material costs | -43.23 | -39.97 | -42.14 | -41.01 |
Employee costs | -14.71 | -14.26 | -13.93 | -12.94 |
Other costs | -23.35 | -24.23 | -22.85 | -23.12 |
Here are some of the stocks that may see significant price movement today: Aurobindo Pharma, Vedanta, Adani Power, etc.
The company announced an operating EBITDA of ₹1,603 Crore, registering a marginal decline of 1% year-on-year.
Here are some of the stocks that may see significant price movement today: LTIMindtree, Paytm, Aurobindo Pharma, etc.
Lannett is a legacy pharmaceutical firm founded in 1942. It is headquartered in Trevose, Pennsylvania, brings with it a deep expertise in manufacturing complex generics.
Here are some of the stocks that may see significant price movement today: FSN E-Commerce, Voltas Limited, Aurobindo Pharma, etc.
Dyrupeg is used primarily to reduce the risk of infection in cancer patients undergoing chemotherapy.
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis
Here are some of the stocks that may see significant price movement today: Gensol Engineering, Oberoi Realty, TVS Motor Company, etc.
Aurobindo Pharma is going to launch Dasatinib in Q1 FY26, which will be in line with its plans to enhance its oncology portfolio in the US generics market.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
